These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16651060)

  • 41. Acid-NSAID/aspirin interaction in peptic ulcer disease.
    Hunt RH; Yuan Y
    Dig Dis; 2011; 29(5):465-8. PubMed ID: 22095011
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
    Shireman TI; Rigler SK
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of compliance with proton pump inhibitors on NSAID treatment.
    Duh MS; Gosselin A; Luo R; Lohoues H; Lewis BE; Crawley JA
    Am J Manag Care; 2009 Oct; 15(10):681-8. PubMed ID: 19845420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
    Chan FK; Abraham NS; Scheiman JM; Laine L;
    Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs.
    Ofman JJ; Maclean CH; Straus WL; Morton SC; Berger ML; Roth EA; Shekelle PG
    Arthritis Rheum; 2003 Aug; 49(4):508-18. PubMed ID: 12910557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI].
    Lems WF; Kuipers EJ
    Ned Tijdschr Geneeskd; 2010; 154(45):A2663. PubMed ID: 21118596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
    Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevention and treatment of NSAID-induced gastroduodenal injury.
    Lanas A
    Curr Treat Options Gastroenterol; 2006 Apr; 9(2):147-56. PubMed ID: 16539875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The prevention of gastropathy and upper abdominal symptoms caused by nonsteroidal anti-inflammatory drugs.
    Vakil N
    Rev Gastroenterol Disord; 2006; 6(4):221-6. PubMed ID: 17224894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.
    Yang M; Wang HT; Zhao M; Meng WB; Ou JQ; He JH; Zou B; Lei PG
    Medicine (Baltimore); 2015 Oct; 94(40):e1592. PubMed ID: 26448006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Adherence with proton pump inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs].
    Pimanov SI; Makarenko EV; Dikareva EA
    Ter Arkh; 2015; 87(4):58-61. PubMed ID: 26087636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Understanding NSAID-PPI-COX-2 interrelationships.
    Singh G
    Drugs Today (Barc); 2004 Mar; 40 Suppl A():21-4. PubMed ID: 15190384
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in The Netherlands.
    Van der Linden MW; Gaugris S; Kuipers EJ; Van den Bemt BJ; van Herk-Sukel MP; Herings RM
    Curr Med Res Opin; 2009 Jan; 25(1):195-204. PubMed ID: 19210152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonsteroidal anti-inflammatory drugs versus selective COX-2 inhibitors in the upper gastrointestinal tract.
    Schölmerich J
    J Cardiovasc Pharmacol; 2006; 47 Suppl 1():S67-71. PubMed ID: 16785832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
    Inotai A; Mészáros A
    Int J Technol Assess Health Care; 2009 Apr; 25(2):190-5. PubMed ID: 19366498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs.
    Thomas D; Ali Z; Zachariah S; Sundararaj KGS; Van Cuyk M; Cooper JC
    Am J Cardiovasc Drugs; 2017 Oct; 17(5):343-346. PubMed ID: 28353025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.